AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6481661 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 0
Study 31342780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual attention training (20 minutes a day, six days/week, for five weeks)
Number of subjects: 40
Study 31342780 — intervention group
Group type: COMPARATOR
Intervention: Control group (language treatment 20 minutes a day, six days/week, for five weeks)
Number of subjects: 40
Study 31342780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual attention training
Number of subjects: 40
Study 31342780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 30090697 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 30090697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27624513 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention model with cognitive-behavioral therapy, care management, and psychopharmacological consultation.
Number of subjects: 49
Study 27624513 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 49
Study 26842203 — intervention group
Group type: EXPERIMENTAL
Intervention: TMX/GOS (Tamoxifen 20 mg/day for 5 years plus Goserelin 3.6 mg injection per month for 2 years)
Number of subjects: 101
Study 26842203 — intervention group
Group type: COMPARATOR
Intervention: TMX (Tamoxifen 20 mg/day for 5 years)
Number of subjects: 101
Study 26842203 — intervention group
Group type: EXPERIMENTAL
Intervention: TMX/GOS
Number of subjects: 101
Study 26842203 — intervention group
Group type: COMPARATOR
Intervention: TMX
Number of subjects: 101
Study 22677304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical preparations (0.1% tretinoin, 0.1% adapalene, 5% dapsone, 1% clindamycin, benzoyl peroxide with adapalene or clindamycin, clindamycin-tretinoin combination)
Number of subjects: 0
Study 22677304 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 0
Study 22677304 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide preparations (2 for 2.5%, 3 for 5.0%)
Number of subjects: 0
Study 22677304 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) for benzoyl peroxide preparations
Number of subjects: 0
Study 22677304 — intervention group
Group type: COMPARATOR
Intervention: Overall vehicle contribution toward drug effect
Number of subjects: 0
Study 20406218 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00821385 (0.5-120 mg kg(‐1))
Number of subjects: 24
Study 20406218 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00821385 (administered to 24 volunteers)
Number of subjects: 24
Study 20406218 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 24
Study 19089199 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid 37%
Number of subjects: 20
Study 19089199 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 20
Study 19089199 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond
Number of subjects: 20
Study 19089199 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study 16278521 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazepril HCl 5/20 mg combination therapy
Number of subjects: 443
Study 16278521 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate 5 mg
Number of subjects: 443
Study 16278521 — intervention group
Group type: COMPARATOR
Intervention: Benazepril HCl 20 mg
Number of subjects: 443
Study 16278521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 443
Study 12403667 — intervention group
Group type: EXPERIMENTAL
Intervention: POTS (n=16)
Number of subjects: 52
Study 12403667 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS (n=20)
Number of subjects: 52
Study 12403667 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (n=52)
Number of subjects: 52
Study 12403667 — intervention group
Group type: COMPARATOR
Intervention: Age-matched healthy women (n=11)
Number of subjects: 52
Study 12403667 — intervention group
Group type: EXPERIMENTAL
Intervention: POTS and NCS
Number of subjects: 52
Study 10442509 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (60 microg given daily i.v. over 2 hours in 250 ml saline, n = 12)
Number of subjects: 24
Study 10442509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml saline, n = 12)
Number of subjects: 24
Study 7540625 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified PCR for detection of H. ducreyi
Number of subjects: 133
Study 7540625 — intervention group
Group type: COMPARATOR
Intervention: Negative control samples
Number of subjects: 133
Study 2349372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg orally, 14 h before)
Number of subjects: 5
Study 2349372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 393381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 139
Study 393381 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus mitomycin C
Number of subjects: 139
Study 393381 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU plus methyl‐CCNU
Number of subjects: 139
Study 393381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (previously treated patients)
Number of subjects: 139
Study 393381 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU plus mitomycin C (previously treated patients)
Number of subjects: 139
Study 393381 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU plus methyl‐CCNU (previously treated patients)
Number of subjects: 139
Study 393381 — intervention group
Group type: EXPERIMENTAL
Intervention: All previously untreated patients
Number of subjects: 139
Study 28762896 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (5 mg/day)
Number of subjects: 850
Study 28762896 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 850
Study 30815125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype knowledge-based application
Number of subjects: 6
Study 30815125 — intervention group
Group type: COMPARATOR
Intervention: Clinical pharmacists
Number of subjects: 6
Study 26923613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day immediately (Group A)
Number of subjects: 3
Study 26923613 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day 7 days after enrollment (Group B)
Number of subjects: 3
Study 26923613 — intervention group
Group type: COMPARATOR
Intervention: No fluoxetine (Group C)
Number of subjects: 3
Study 25224993 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in patients with self-reported depression
Number of subjects: 196
Study 25224993 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in patients with smoking
Number of subjects: 196
Study 25224993 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in physically inactive patients
Number of subjects: 196
Study 25224993 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in patients during spring season
Number of subjects: 196
Study 25224993 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight salivary cortisol (MSC) levels in patients with HbA1c >70 mmol/mol (>8.6%)
Number of subjects: 196
Study 25224993 — intervention group
Group type: COMPARATOR
Intervention: Reference group of non-depressed patients with a healthy lifestyle (physically active and non-smoking)
Number of subjects: 196
Study 22179140 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA scans after repositioning
Number of subjects: 31
Study 22179140 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA scans after daily activities
Number of subjects: 31
Study 22179140 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA scans before and after breakfast consumption
Number of subjects: 31
Study 20004725 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (target blood alcohol level of 50 mg%)
Number of subjects: 26
Study 20004725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17285425 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (10 microg/kg at induction and 5 microg/kg/h infusion for maintenance)
Number of subjects: 50
Study 17285425 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (3 microg/kg at induction and 1 microg/kg/min infusion for maintenance)
Number of subjects: 50
Study 16540790 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg orally, once daily for 14 days) with ORS
Number of subjects: 2002
Study 16540790 — intervention group
Group type: COMPARATOR
Intervention: ORS alone (control group)
Number of subjects: 2002
Study 12889593 — intervention group
Group type: EXPERIMENTAL
Intervention: NICHD Maternal Fetal Medicine Units Network trials (specific interventions not detailed)
Number of subjects: 0
Study 12889593 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes made to organization and methodology of the Network
Number of subjects: 0
Study 11196120 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine
Number of subjects: 72
Study 11196120 — intervention group
Group type: COMPARATOR
Intervention: Vehicle solution
Number of subjects: 72
Study 7855966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual liquid preparation
Number of subjects: 22
Study 7855966 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tablet
Number of subjects: 22
Study 7855966 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous nasal spray
Number of subjects: 22
Study 7855966 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled absorption 3 and 4 mg tablets
Number of subjects: 22
Study 7855966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7855966 — intervention group
Group type: EXPERIMENTAL
Intervention: Home trial use of controlled absorption tablets
Number of subjects: 22
Study 1945288 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol maleate 0.5%
Number of subjects: 5
Study 1945288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7060486 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin administration via jet injector
Number of subjects: 10
Study 7060486 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous heparin administration via disposable syringe
Number of subjects: 10
Study 31762400 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month behavioral intervention
Number of subjects: 244
Study 31762400 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 244
Study 30506427 — intervention group
Group type: EXPERIMENTAL
Intervention: Football (1 hour, twice weekly)
Number of subjects: 214
Study 30506427 — intervention group
Group type: COMPARATOR
Intervention: Usual care (15-30 min telephone session)
Number of subjects: 214
Study 28700680 — intervention group
Group type: EXPERIMENTAL
Intervention: LF‐MA
Number of subjects: 74
Study 28700680 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐MA
Number of subjects: 74
Study 28700680 — intervention group
Group type: EXPERIMENTAL
Intervention: LF‐EA
Number of subjects: 74
Study 28700680 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐EA
Number of subjects: 74
Study 28700680 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture groups
Number of subjects: 74
Study 28700680 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency treatment groups
Number of subjects: 74
Study 28700680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency treatment groups
Number of subjects: 74
Study 25582611 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1.5 mg/kg
Number of subjects: 54
Study 25582611 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 0.5 mg/kg
Number of subjects: 54
Study 25582611 — intervention group
Group type: COMPARATOR
Intervention: placebo (NaCl 0.9%)
Number of subjects: 54
Study 24166335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy (MDFT)
Number of subjects: 109
Study 24166335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 109
Study 21890776 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg once daily
Number of subjects: 116
Study 21890776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 400 mg once daily (after 14 days of 200 mg)
Number of subjects: 116
Study 19920270 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone, 3 mg for the first 14 nights of CPAP
Number of subjects: 160
Study 19920270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 17353335 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 34
Study 17353335 — intervention group
Group type: COMPARATOR
Intervention: Optimal pain medication (OPM)
Number of subjects: 34
Study 17353335 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV) after 2 weeks of OPM
Number of subjects: 34
Study 14694167 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha to maintain hemoglobin between 120 and 130 g/L (group A)
Number of subjects: 155
Study 14694167 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alpha to maintain hemoglobin between 90 and 100 g/L (group B)
Number of subjects: 155
Study 14694167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 155
Study 10925934 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 5 microg x mL(‐1) (group E)
Number of subjects: 12
Study 10925934 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine (group L)
Number of subjects: 12
Study 8873934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestream smoke inhalation
Number of subjects: 20
Study 8873934 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study 1859006 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane and nitrous oxide anesthesia (25% nitrous oxide)
Number of subjects: 47
Study 1859006 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane and nitrous oxide anesthesia (50% nitrous oxide)
Number of subjects: 47
Study 1859006 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane and nitrous oxide anesthesia (75% nitrous oxide)
Number of subjects: 47
Study 1859006 — intervention group
Group type: COMPARATOR
Intervention: isoflurane and oxygen anesthesia
Number of subjects: 47
Study 6341271 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention programme
Number of subjects: 6000
Study 6341271 — intervention group
Group type: EXPERIMENTAL
Intervention: Older girls (11-12 years) in treatment group
Number of subjects: 6000
Study 6341271 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger boys (10-11 years) in treatment group
Number of subjects: 6000
Study 6341271 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes and knowledge changes
Number of subjects: 6000
Study 31003644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (PG)
Number of subjects: 52
Study 31003644 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 52
Study 29653812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2800 IU daily for 8 weeks)
Number of subjects: 200
Study 29653812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 25661470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led heart failure specific education session with three-month telephone follow-up in addition to standard medical treatment
Number of subjects: 110
Study 25661470 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment only
Number of subjects: 110
Study 23032238 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing calcium sodium phosphosilicate
Number of subjects: 20
Study 23032238 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste containing potassium nitrate (positive control)
Number of subjects: 20
Study 20424826 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 40
Study 20424826 — intervention group
Group type: COMPARATOR
Intervention: TOT
Number of subjects: 40
Study 18281099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan Depletion (TD)
Number of subjects: 54
Study 18281099 — intervention group
Group type: COMPARATOR
Intervention: Sham Depletion
Number of subjects: 54
Study 16001659 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha), ribavirin, and ursodeoxycholic acid (UDCA)
Number of subjects: 20
Study 12423432 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 215
Study 12423432 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics/topical treatments
Number of subjects: 215
Study 10472699 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms kg-1)
Number of subjects: 28
Study 10472699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10472699 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 28
Study 10472699 — intervention group
Group type: COMPARATOR
Intervention: Clonidine and Placebo
Number of subjects: 28
Study 8910174 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.25 mg/kg IV
Number of subjects: 132
Study 8910174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg IV
Number of subjects: 132
Study 8910174 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV saline
Number of subjects: 132
Study 1656521 — intervention group
Group type: EXPERIMENTAL
Intervention: Muesli
Number of subjects: 24
Study 1656521 — intervention group
Group type: COMPARATOR
Intervention: Standard breakfast
Number of subjects: 24
Study 1656521 — intervention group
Group type: COMPARATOR
Intervention: Standard breakfast with 100 mg miglitol
Number of subjects: 24
Study 1656521 — intervention group
Group type: EXPERIMENTAL
Intervention: Muesli with 100 mg miglitol
Number of subjects: 24
Study 6358896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous timolol treatment
Number of subjects: 144
Study 6358896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 31048509 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (8 weeks of aerobic and resistance exercise with behaviour change strategies and symptom support)
Number of subjects: 92
Study 31048509 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 92
Study 31048509 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study 29590122 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walk distance >400 m
Number of subjects: 0
Study 29590122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline six-minute walk distance Q4 (>430 m)
Number of subjects: 0
Study 29590122 — intervention group
Group type: EXPERIMENTAL
Intervention: Month 6 six-minute walk distance Q4 (>455 m)
Number of subjects: 0
Study 29590122 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in six-minute walk distance at Month 6
Number of subjects: 0
Study 27434081 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min stepper test (6MST)
Number of subjects: 31
Study 25217875 — intervention group
Group type: EXPERIMENTAL
Intervention: EmbryoScope time‐lapse monitoring system (TMS)
Number of subjects: 843
Study 25217875 — intervention group
Group type: COMPARATOR
Intervention: Standard incubator (SI)
Number of subjects: 843
Study 22875601 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg single dose)
Number of subjects: 50
Study 22875601 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study 20236598 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg)
Number of subjects: 60
Study 20236598 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium + Neostigmine (0.04 mg/kg) and Atropine (0.02 mg/kg)
Number of subjects: 60
Study 17563138 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment gambling behavior
Number of subjects: 178
Study 17563138 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative behavioral indicators
Number of subjects: 178
Study 17707848 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed women with CHD (BDI score > or =19)
Number of subjects: 121
Study 15065961 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week cognitive-behavioral treatment for primary anxiety disorders
Number of subjects: 86
Study 15065961 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive responders to anxiety treatment
Number of subjects: 86
Study 11876837 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.1 mg . kg(‐1) subcutaneously at 10 pm every evening for 14 days)
Number of subjects: 33
Study 11876837 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 33
Study 11876837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 33
Study 11876837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9339609 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 0
Study 9339609 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 0
Study 9339609 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators only (Control)
Number of subjects: 0
Study 1286545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp (Hy)
Number of subjects: 17
Study 1286545 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal model (MIN)
Number of subjects: 17
Study 1286545 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened intravenous glucose tolerance test (IVGTT)
Number of subjects: 17
Study 1286545 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of glucose with model assessment (C.I.G.M.A.)
Number of subjects: 17
Study 1286545 — intervention group
Group type: COMPARATOR
Intervention: All methodologies combined
Number of subjects: 17
Study 3891346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine treatment (10 mg orally at onset, after 30 min, then every 6 h)
Number of subjects: 57
Study 3891346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57